How do toxin A/B enzyme immunoassay and molecular PCR testing compare for diagnosing Clostridioides difficile infection?

Molecular PCR Testing is Superior to Toxin A/B EIA for Diagnosing C. difficile Infection

Do not use toxin A/B enzyme immunoassay (EIA) alone for C. difficile diagnosis—it misses too many cases due to poor sensitivity (low, ~42-68%), while molecular PCR testing demonstrates high sensitivity (>90%) and should be incorporated into your diagnostic algorithm 1.

The Core Problem with Each Test

Toxin A/B EIA Limitations

• Unacceptably low sensitivity: Toxin EIAs detect only 42-68% of true CDI cases 2, 1
• Detects free toxins in stool, which requires high toxin concentrations
• Variable performance across commercial kits 1
• Clinical impact: Using EIA alone artificially reduces reported CDI cases by missing genuine infections 3

Molecular PCR Advantages and Caveats

• High sensitivity (>90%) for detecting toxigenic C. difficile 2, 1
• Rapid turnaround time (~50 minutes for platforms like Xpert) 4
• Detects toxin genes (tcdA/tcdB), not actual toxin production
• Key limitation: Cannot distinguish active infection from asymptomatic colonization, as up to 46% of hospitalized patients may carry toxigenic strains without disease 2

Recommended Diagnostic Approach

The 2018 IDSA/SHEA guidelines advocate for multi-step algorithmic testing rather than single-test strategies 1:

Optimal Algorithm (GDH/PCR-based)

1. Screen with GDH immunoassay (high sensitivity, detects all C. difficile)
2. If GDH positive → Reflex to PCR for toxin gene detection
3. This approach achieves sensitivity of 0.91-0.98 and specificity of 0.96-0.98 2

Alternative Algorithm (if PCR unavailable)

1. GDH screen
2. If positive → Toxin EIA
3. If discordant → Arbitrate with PCR or toxigenic culture

Critical Clinical Pitfalls

Only test patients with clinically significant diarrhea (≥3 unformed stools in 24 hours). Testing formed stools or asymptomatic patients dramatically increases false-positive rates with PCR 2, 1.

When PCR is Positive but Toxin EIA is Negative (PCR+/EIA-)

This scenario occurs frequently and creates management dilemmas. Recent data shows 5:

• 9.6% of PCR+/EIA- patients develop CDI-related complications
• Predictors of true disease include:
  • Baseline severe disease by IDSA criteria (OR 5.84)
  • Fever >38.5°C (OR 4.61)
  • Fulminant colitis (OR 84.7)
• Clinical outcomes in treated PCR+/EIA- patients mirror those of PCR+/EIA+ patients, suggesting many represent true infections

Treat PCR+/EIA- patients if they have clinical features of CDI (diarrhea, fever, leukocytosis, abdominal pain), as withholding treatment risks complications in 15% of untreated cases 5.

Why Not Use Toxin EIA Alone?

A 2026 process improvement study demonstrated that EIA showed <30% sensitivity compared to PCR, artificially reducing hospital-onset CDI reporting while missing genuine infections 3. The study concluded that implementing EIA as a confirmatory test offers "limited clinical value in CDI management" and that provider education on appropriate testing criteria is more effective than relying on insensitive toxin detection 3.

Practical Implementation

For rapid diagnosis with best sensitivity: Use standalone PCR testing (Xpert C. difficile or BD GeneOhm) with strict pre-test criteria enforcement 6, 4.

For cost-effectiveness with high accuracy: Implement GDH screening followed by PCR confirmation for positive results 2, 1.

Never use toxin A/B EIA as your sole diagnostic test—you will miss 30-60% of true CDI cases, delaying treatment and worsening patient outcomes 1, 3.